A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Inclusion Criteria:

   - Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the
   time of informed consent.

   - Must self-identify as either Black or African American in race in the open label
   addenda.

   - Have severe or very severe AA, as determined by all of the following:

      - Current AA episode of more than 6 months' duration and hair loss encompassing
      ≥50% of the scalp, as measured by SALT Alopecia Areata Investigator Global
      Assessment (AA-IGA) of 3 or 4) at screening and baseline.

      - No spontaneous improvement over the past 6 months.

      - Current episode of severe or very severe AA of less than 8 years.

   - Male or nonpregnant, nonbreastfeeding female participants.

Exclusion Criteria:

   - Primarily "diffuse" type of AA.

   - Are currently experiencing other forms of alopecia or any other concomitant conditions
   that would interfere with evaluations of the effect of study medication on AA.

   - Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate
   response (for example, absence of significant terminal hair growth after at least 12
   weeks of treatment).